ActoFactor™ Recombinant Human Cerebral cavernous malformation 3
- Specification
 - Q & A
 - Customer Review
 
Cat.No.
CSC-CTK0630
Description
Cerebral cavernous malformations (CCMs) are sporadically acquired or inherited vascular lesions of the central nervous system consisting of clusters of dilated thin-walled blood vessels that predispose individuals to seizures and stroke. Mutations in CCM-1, CCM-2, or CCM-3 lead to cerebral cavernous malformations, one of the most common hereditary vascular diseases of the brain. Endothelial cells within these lesions are the main disease compartments. Here, we show that adenoviral CCM-3 expression inhibits endothelial cell migration, proliferation, and tube formation while down regulation of endogenous CCM-3 results in increased formation of tube- like structures. Adenoviral CCM-3 expression does not induce apoptosis under normal endothelial cell culture conditions but protects endothelial cells from staurosporine-induced cell death. Tyrosine kinase activity profiling suggests that CCM-3 supports PDPK-1/Akt-mediated endothelial cell quiescence and survival. The CCM-3 is fused to a N-terminal His-tag (6x His). It is a 26.7 kDa protein containing 231 amino acid residues.
Species
                                Human
                            Product Overview
                                Human CCM3 expressed in E.coli
                            Molecular Mass
                                26.7 kDa
                            Size
                                CAT# CSC-CTK0630-20 (20 μg); CAT# CSC-CTK0630-100 (100 μg)
                            Expression System
                                E.coli
                            Purity
                                Greater than 95% as determined by SDS-PAGE analysis.
                            Activity
                                N/A
                            Endotoxin Level
                                Less than 1 EU/μg.
                            Formulation
                                Lyophilized from a steril-filtered protein solution in PBS without any stabilizers.
                            Reconstitution
                                Please centrifuge product briefly before opening vial. The lyophilized protein should be reconstituted in sterile, ultra-pure water to a concentration of 0.1-1.0 mg/ml. This solution can then be diluted into other aqueous buffers and stored at -20°C for future use.
                            Storage & Stability
                                The lyophilized protein, though stable at room temperature for up to 3 weeks, is best stored desiccated at -20°C. Reconstituted protein should be used immediately or stored long-term in undiluted working aliquots at -20°C. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid repeated freeze-thaw cycles.
                            Citation Guidance
                        
                            If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no.
                            
                                If your paper has been published, please click here
                                to submit the PubMed ID of your paper to get a coupon.
                            
                        
                    Ask a Question
Write your own review